Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Receivables (2018 - 2025)

Addex Therapeutics' Receivables history spans 8 years, with the latest figure at $25132.2 for Q4 2025.

  • On a quarterly basis, Receivables fell 6.23% to $25132.2 in Q4 2025 year-over-year; TTM through Dec 2025 was $25132.2, a 6.23% decrease, with the full-year FY2025 number at $24227.5, down 9.61% from a year prior.
  • Receivables came in at $25132.2 for Q4 2025, down from $64064.4 in the prior quarter.
  • The five-year high for Receivables was $1.3 million in Q2 2021, with the low at $25132.2 in Q4 2025.
  • Historically, Receivables has averaged $389322.3 across 5 years, with a median of $424215.1 in 2023.
  • Biggest five-year swings in Receivables: surged 1147.63% in 2021 and later crashed 93.19% in 2025.
  • Year by year, Receivables stood at $319695.0 in 2021, then skyrocketed by 74.32% to $557288.0 in 2022, then crashed by 69.4% to $170532.7 in 2023, then plummeted by 84.28% to $26802.9 in 2024, then dropped by 6.23% to $25132.2 in 2025.
  • Business Quant data shows Receivables for ADXN at $25132.2 in Q4 2025, $64064.4 in Q3 2025, and $46430.1 in Q2 2025.